Viewing Study NCT05057065



Ignite Creation Date: 2024-05-06 @ 4:41 PM
Last Modification Date: 2024-10-26 @ 2:14 PM
Study NCT ID: NCT05057065
Status: UNKNOWN
Last Update Posted: 2021-09-27
First Post: 2021-09-08

Brief Title: A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
Sponsor: Hong Ren
Organization: The Second Affiliated Hospital of Chongqing Medical University

Study Overview

Official Title: Disease Progression and Intervention of Chronic HepatitisB Based on Diabetes and Hyperlipidemia
Status: UNKNOWN
Status Verified Date: 2021-09
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: HBVhepatitis B virus with metabolic comorbidities may accelerate liver disease progression and increase the risk of HCCHepatocellular Carcinomadevelopment It is reported combination of metabolic diseases and CHB is associated with substantially increased rates of liver cirrhosis and secondary liver-related events compared to CHB alone Consequently hepatitis B patients with metabolic comorbidities warrant particular attention in disease surveillance and evaluation of treatment indications
Detailed Description: Primary objective

To evaluate the impact of metabolic disease on the progression of chronic hepatitis B

To observe HBsAgHBeAgHBV DNA changes HBsAg seroconversion
To determine high rates of Liver Cirrhosis and Hepatocellular Carcinoma

Group 1 CHB with diabetes Group 2 CHB with hyperlipemia Group 3 CHB without metabolic diseases

Study Duration in months 24 months

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None